Is P8A.SI stock a buy after the recent drop?

P8A.SI stock shows an oversold technical setup, but fundamentals are mixed (EPS -0.05). For short-term traders a small, risk-controlled buy on a confirmed bounce is reasonable. Long-term buyers should wait for earnings improvement and receivables reduction.

What price targets should I watch for P8A.SI stock?

Near-term targets are **S$0.17** and **S$0.23**. Meyka AI's yearly forecast is **S$0.30423**, implying ~**111.30%** upside from **S$0.144**. Use targets with staged profit-taking and risk controls.

What are the key risks for P8A.SI stock traders?

Key risks include low liquidity, long receivables (**255.59** days), negative EPS (**-0.05**), and the potential for further downside below the year low **S$0.127**. Tight stops and small size reduce these risks.

How does sector context affect P8A.SI stock?

Cordlife sits in Healthcare diagnostics where demand is steady but competitive. The stock’s **PB 0.34** is below sector averages, suggesting valuation support, but earnings recovery is required for durable gains.

SG Stocks

S$0.144 pre-market P8A.SI Cordlife Group (SES) 14 Feb 2026: Oversold bounce

ByHuzaifa Zahoor February 14, 2026

We see Cordlife Group Limited (P8A.SI stock) trading at S$0.144 in the Singapore Exchange (SES) pre-market on 14 Feb 2026, down -4.00% from the prior close. The technical picture shows an RSI of 26.88, placing the stock in oversold territory and setting a classic oversold-bounce scenario. Liquidity is light with volume at 2,000.00 shares versus an average of 17,328.00, so moves may be uneven. We outline a measured trade plan, key catalysts, and risk controls for short-term bounces and a medium-term view tied to Meyka AI forecasts.